ArticleDiabetes spectrum : a publication of the American Diabetes Association2016
Recognizing and Appropriately Treating Latent Autoimmune Diabetes in Adults.
Article in Diabetes spectrum : a publication of the American Diabetes Association, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed.
- Impact of GAD-65 antibody detection on antihyperglycemic therapy in T2D.Endocrine connections · 2026Article
- Distinguishing different psychiatric disorders using DDx-PRS.Nature genetics · 2026Article
- Article
- Explainable machine learning model for in-hospital hypoglycemia risk in patients with latent autoimmune diabetes in adults.Frontiers in immunology · 2026Article
- Autoimmune Phenotype Confirmation Intervals and Clinical Indicators in Patients With Latent Autoimmune Diabetes in Adults (LADA) in Southwest China: A Multicenter Retrospective Cross-Sectional Study.Journal of diabetes research · 2026Observational
- Evaluation of distinct and similar pathological features between diabetes and Alzheimer's disease.EXCLI journal · 2026Review
- Proper diagnosis of latent autoimmune diabetes in adults prompts appropriate pharmacotherapy; C-peptide is just one component.Journal of diabetes and metabolic disorders · 2025Article
- Lean type 2 diabetes: the overlooked epidemic reshaping global health.Diabetology & metabolic syndrome · 2025Review
- Deciphering disease-specific glycosylation: unraveling diabetes subtypes through serum glycopattern.Analytical and bioanalytical chemistry · 2025Article
- Eye Focusing Ability Can Predict Glycated Hemoglobin Level of Type-1 Diabetes Patients.Health science reports · 2025Article
- Article
- Unveiling the Therapeutic Potential of the Second-Generation Incretin Analogs Semaglutide and Tirzepatide in Type 1 Diabetes and Latent Autoimmune Diabetes in Adults.Journal of clinical medicine · 2025Review
- Autoimmune pathogenesis of gestational diabetes mellitus: the risk of progression to type 1 diabetes mellitus.Frontiers in endocrinology · 2025Review
- Latent Autoimmune Diabetes in Adults Following Bariatric Surgery-Induced Hypoglycemia in a 36-Year-Old Woman.Cureus · 2024Article
- Anti-inflammatory benefits of semaglutide: State of the art.Journal of clinical & translational endocrinology · 2024Review
- Latent Autoimmune Diabetes in Adults and a Continuous Glucose Monitoring Device: An Unfortunate Outcome.Cureus · 2023Article
- Article
- Article
- Hepatic benefits of sodium-glucose cotransporter 2 inhibitors in liver disorders.EXCLI journal · 2023Review
- Benefits of GLP-1 Mimetics on Epicardial Adiposity.Current medicinal chemistry · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.